Preferably, said adenoviral replicon comprises a recombinant adenovirus with a fusion between DNA from Ad5 and subgroup B adenoviral DNA.
The invention further comprises a method of producing an adenoviral vector, and a composition comprising a serotype 41 or a serotype 35 adenoviral vector and a carrier.
The adenoviral vector may be a replication deficient adenoviral vector which is free of at least the majority of the E1 and E3 DNA sequences.
An adenoviral vector wherein the adenoviral genome has been modified to reduce the host immune and inflammatory responses to the vector.
An adenoviral supervector system is disclosed that is capable of expressing more than 7.5 kilobases of heterologous DNA in a replication defective adenoviral vector.
The present invention provides a recombinant ovine adenovirus vector.
The vector comprises an ovine adenovirus genome in which a heterologous nucleic acid molecule is inserted between coding regions of transcription units which are adjacent in ovine adenovirus genome.
The present invention provides a recombinant adenovirus vector targeted by zipper peptides.
The invention provides a method for identifying an adenoviral replicon capable of eliminating a target cell, comprising contacting a representative cell with said adenoviral replicon and observing any detrimental effect.
The resultant cleavage products are then ligated to produce the subject recombinant adenovirus genome.
The trimer exhibits reduced affinity for a native substrate than a native adenoviral fiber trimer.